001     156966
005     20240229123124.0
024 7 _ |a 10.1158/1055-9965.EPI-20-0184
|2 doi
024 7 _ |a pmid:32467345
|2 pmid
024 7 _ |a 1055-9965
|2 ISSN
024 7 _ |a 1538-7755
|2 ISSN
024 7 _ |a altmetric:83206583
|2 altmetric
037 _ _ |a DKFZ-2020-01271
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Lujan-Barroso, Leila
|0 0000-0001-6224-1764
|b 0
245 _ _ |a Menstrual Factors, Reproductive History, Hormone Use, and Urothelial Carcinoma Risk: A Prospective Study in the EPIC Cohort.
260 _ _ |a Philadelphia, Pa.
|c 2020
|b AACR
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1597321620_21565
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a Volume 29, Issue 8, 1 August 2020, Pages 1654-1664
520 _ _ |a Urothelial carcinoma is the predominant (95%) bladder cancer subtype in industrialized nations. Animal and epidemiologic human studies suggest that hormonal factors may influence urothelial carcinoma risk.We used an analytic cohort of 333,919 women from the European Prospective Investigation into Cancer and Nutrition Cohort. Associations between hormonal factors and incident urothelial carcinoma (overall and by tumor grade, tumor aggressiveness, and non-muscle-invasive urothelial carcinoma) risk were evaluated using Cox proportional hazards models.During a mean of 15 years of follow-up, 529 women developed urothelial carcinoma. In a model including number of full-term pregnancies (FTP), menopausal status, and menopausal hormone therapy (MHT), number of FTP was inversely associated with urothelial carcinoma risk (HR≥5vs1 = 0.48; 0.25-0.90; Ptrend in parous women = 0.010) and MHT use (compared with nonuse) was positively associated with urothelial carcinoma risk (HR = 1.27; 1.03-1.57), but no dose response by years of MHT use was observed. No modification of HRs by smoking status was observed. Finally, sensitivity analyses in never smokers showed similar HR patterns for the number of FTP, while no association between MHT use and urothelial carcinoma risk was observed. Association between MHT use and urothelial carcinoma risk remained significant only in current smokers. No heterogeneity of the risk estimations in the final model was observed by tumor aggressiveness or by tumor grade. A positive association between MTH use and non-muscle-invasive urothelial carcinoma risk was observed.Our results support that increasing the number of FTP may reduce urothelial carcinoma risk.More detailed studies on parity are needed to understand the possible effects of perinatal hormone changes in urothelial cells.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Botteri, Edoardo
|b 1
700 1 _ |a Caini, Saverio
|b 2
700 1 _ |a Ljungberg, Börje
|0 0000-0002-4121-3753
|b 3
700 1 _ |a Roswall, Nina
|0 0000-0003-3071-1658
|b 4
700 1 _ |a Tjønneland, Anne
|0 0000-0003-4385-2097
|b 5
700 1 _ |a Bueno-de-Mesquita, Bas
|b 6
700 1 _ |a Gram, Inger T
|0 0000-0002-0031-4152
|b 7
700 1 _ |a Tumino, Rosario
|0 0000-0003-2666-414X
|b 8
700 1 _ |a Kiemeney, Lambertus A
|0 0000-0002-2368-1326
|b 9
700 1 _ |a Liedberg, Fredrik
|0 0000-0001-8193-0370
|b 10
700 1 _ |a Stocks, Tanja
|b 11
700 1 _ |a Gunter, Marc J
|b 12
700 1 _ |a Murphy, Neil
|b 13
700 1 _ |a Cervenka, Iris
|b 14
700 1 _ |a Fournier, Agnès
|0 0000-0001-8380-3439
|b 15
700 1 _ |a Kvaskoff, Marina
|0 0000-0002-4557-3772
|b 16
700 1 _ |a Häggström, Christel
|b 17
700 1 _ |a Overvad, Kim
|b 18
700 1 _ |a Lund, Eiliv
|b 19
700 1 _ |a Waaseth, Marit
|0 0000-0002-1318-3972
|b 20
700 1 _ |a Turzanski-Fortner, Renée
|0 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2
|b 21
|u dkfz
700 1 _ |a Kühn, Tilman
|0 P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe
|b 22
|u dkfz
700 1 _ |a Menéndez, Virginia
|b 23
700 1 _ |a Sánchez, Maria-Jose
|0 0000-0003-4817-0757
|b 24
700 1 _ |a Santiuste, Carmen
|b 25
700 1 _ |a Perez-Cornago, Aurora
|0 0000-0002-5652-356X
|b 26
700 1 _ |a Zamora-Ros, Raul
|0 0000-0002-6236-6804
|b 27
700 1 _ |a Cross, Amanda J
|0 0000-0002-0893-2377
|b 28
700 1 _ |a Trichopoulou, Antonia
|b 29
700 1 _ |a Karakatsani, Anna
|0 0000-0002-3275-2026
|b 30
700 1 _ |a Peppa, Eleni
|b 31
700 1 _ |a Palli, Domenico
|0 0000-0002-5558-2437
|b 32
700 1 _ |a Krogh, Vittorio
|b 33
700 1 _ |a Sciannameo, Veronica
|b 34
700 1 _ |a Mattiello, Amalia
|b 35
700 1 _ |a Panico, Salvatore
|b 36
700 1 _ |a van Gils, Carla H
|b 37
700 1 _ |a Onland-Moret, N Charlotte
|0 0000-0002-2360-913X
|b 38
700 1 _ |a Barricarte, Aurelio
|0 0000-0001-6750-1270
|b 39
700 1 _ |a Amiano, Pilar
|b 40
700 1 _ |a Khaw, Kay-Tee
|b 41
700 1 _ |a Boeing, Heiner
|b 42
700 1 _ |a Weiderpass, Elisabete
|0 0000-0003-2237-0128
|b 43
700 1 _ |a Duell, Eric J
|0 0000-0001-5256-0163
|b 44
773 _ _ |a 10.1158/1055-9965.EPI-20-0184
|g p. cebp;1055-9965.EPI-20-0184v2
|0 PERI:(DE-600)2036781-8
|n 8
|p 1654-1664
|t Cancer epidemiology, biomarkers & prevention
|v 29
|y 2020
|x 1538-7755
909 C O |o oai:inrepo02.dkfz.de:156966
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 21
|6 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 22
|6 P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2020
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2020-01-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
|d 2020-01-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2020-01-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2020-01-17
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
|d 2020-01-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2020-01-17
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
|d 2020-01-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-01-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2020-01-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2020-01-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2020-01-17
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCER EPIDEM BIOMAR : 2018
|d 2020-01-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2020-01-17
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CANCER EPIDEM BIOMAR : 2018
|d 2020-01-17
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21